HCPCS | Generic Name | Brand Name | Strength | SEER*Rx Category (Descending) | Major Drug Class | Minor Drug Class | Oral (Y/N) | FDA Approval Year | FDA Discontinuation Year | CMS Effective Date | CMS Discontinuation Date | Status |
---|---|---|---|---|---|---|---|---|---|---|---|---|
J7506 | Prednisone | Deltasone, PredniSONE Intensol, Rayos | 5 mg | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Yes | 1974 | Jan. 1, 1989 | Dec. 31, 2015 | No Longer Used | |
NA | Apalutamide | Erleada | 60mg | Hormonal Therapy | Androgen Receptor Inhibitor | Non-Steroidal | Yes | 2018 | In Use | |||
NA | Darolutamide | Nubeqa | 300mg | Hormonal Therapy | Androgen Receptor Inhibitor | Non-Steroidal | Yes | 2019 | In Use | |||
NA | Hydrocortisone | Cortef | 5mg, 10mg, 20mg | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Yes | 1952 | In Use | |||
NA | Relugolix | Orgovyx | 120mg | Hormonal Therapy | Androgen Receptor Inhibitor | GnRH Receptor Antagonist | Yes | 2020 | In Use | |||
NA | Megestrol Acetate | Megace | 20mg, 40mg | Hormonal Therapy | Progestin | Yes | 1988 | In Use | ||||
J1952 | Leuprolide Mesylate | Camcevi | 1mg | Hormonal Therapy | GnRH Agonist | No | 2021 | Jan. 26, 2022 | In Use | |||
J1932 | Lanreotide (Cipla) | Lanreotide Acetate | 1mg | Hormonal Therapy | Somatostatin Analog | No | 2021 | Sept. 27, 2022 | In Use | |||
J9393 | Fulvestrant (Teva) | Fulvestrant (Teva) | 25mg | Hormonal Therapy | Estrogen Receptor Antagonist | No | 2019 | Dec. 21, 2022 | In Use | |||
J9394 | Fulvestrant (Fresnius) | Fulvestrant (Fresnius) | 25mg | Hormonal Therapy | Estrogen Receptor Antagonist | No | 2019 | Dec. 21, 2022 | In Use | |||
NA | Elacestrant | Orserdu | Multiple | Hormonal Therapy | Estrogen Receptor Antagonist | ERÉ‘ | Yes | 2023 | In Use | |||
J1010 | Methylprednisolone acetate | Methylprednisolone acetate | 1mg | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | No | 1959 | April 17, 2024 | In Use | ||
J2919 | Methylprednisolone sodium succinate | Methylprednisolone sodium succinate | 5mg | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | No | 1959 | April 17, 2024 | In Use | ||
NA | Acalabrutinib | Calquence | 100 mg | Chemotherapy | Tyrosine Kinase Inhibitor | Bruton's Tyrosine Kinase (Btk) /BCR | Yes | 2017 | In Use | |||
NA | Afatinib | Gliotrif | 20 mg | Chemotherapy | Tyrosine Kinase Inhibitor | EGFR | Yes | 2013 | In Use | |||
NA | Afatinib | Gliotrif | 30 mg | Chemotherapy | Tyrosine Kinase Inhibitor | EGFR | Yes | 2013 | In Use | |||
NA | Afatinib | Gliotrif | 40 mg | Chemotherapy | Tyrosine Kinase Inhibitor | EGFR | Yes | 2013 | In Use | |||
NA | Abemaciclib | Verzenio | 50 mg | Chemotherapy | Cyclin Dependent Kinase Inhibitor | CDK 4/6 | Yes | 2017 | In Use | |||
NA | Abemaciclib | Verzenio | 100 mg | Chemotherapy | Cyclin Dependent Kinase Inhibitor | CDK 4/6 | Yes | 2017 | In Use | |||
NA | Abemaciclib | Verzenio | 150 mg | Chemotherapy | Cyclin Dependent Kinase Inhibitor | CDK 4/6 | Yes | 2017 | In Use | |||
NA | Abemaciclib | Verzenio | 200 mg | Chemotherapy | Cyclin Dependent Kinase Inhibitor | CDK 4/6 | Yes | 2017 | In Use | |||
NA | Alectinib | Alecensa | 150 mg | Chemotherapy | Tyrosine Kinase Inhibitor | ALK | Yes | 2015 | In Use | |||
NA | Altretamine | Hexalen | 50 mg | Chemotherapy | Alkylating Agent | Triazines | Yes | 1990 | 2019 | In Use | ||
J9017 | Arsenic Trioxide | Trisenox | 1 mg | Chemotherapy | Miscellaneous Agent | PML/RARa | No | 2000 | Jan. 1, 2002 | In Use | ||
C9012 | Arsenic Trioxide | Trisenox | unspecified | Chemotherapy | Miscellaneous Agent | PML/RARa | No | 2000 | Jan. 1, 2001 | Dec. 31, 2001 | No Longer Used |
Found 716 results in 3 milliseconds — Export these results
The use of NA indicates that the HCPCS code was Not Available. NA may mean that a) the HCPCS code has
not yet been created (new drug), b) the drug is given as an oral drug or alternative route (only in
specific instances are HCPCS assigned to these medications), or c) the HCPCS could not be found or is
truly not available.